Study of NG101m therapy after standard treatment for newly diagnosed glioblastoma
Treatments studied
Part of Cancer clinical trials.
This study tests an experimental treatment given after the standard first treatment (chemotherapy and radiation) for newly diagnosed glioblastoma, a type of brain cancer. It aims to see if this extra treatment helps keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been newly diagnosed with glioblastoma and are scheduled to receive (or have just completed) standard treatment that combines chemotherapy and radiation.
- Your blood counts and kidney and liver function are within acceptable ranges.
- You are able to be off strong steroid medications (if any) and you are not on any other alternative cancer treatments.
- You do not have a history of autoimmune disease, stomach ulcers, or allergies to the trial's ingredients.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests the safety and early effectiveness of BEY1107 combined with temozolomide in adults whose glioblastoma has come back or kept growing after standard treatment. If you qualify, you may be able to receive this combination while the researchers closely monitor side effects and tumor response.
This study tests a new medicine (MT-125) combined with standard radiation and chemotherapy for people with newly diagnosed glioblastoma that has a specific gene change (MGMT methylated). The goal is to see if it is safe and tolerable, and to look for early signs it might help.
This trial tests whether adding a drug called mycophenolate mofetil to the standard treatment (radiation therapy and temozolomide) helps people with a newly diagnosed brain cancer called glioblastoma. The drug may boost the effect of the standard treatment.
This trial tests an oral drug called NBM-BMX for people with advanced solid tumors that have not responded to other treatments, or for people with newly diagnosed glioblastoma (a type of brain cancer). The study aims to see if the drug is safe and effective.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests a new two-part treatment (DB107-RRV and DB107-FC) combined with radiation, with or without the chemotherapy drug temozolomide, for people with newly diagnosed high-grade glioma. It aims to see if this approach is safe and effective.
Hear when a new Glioblastoma Multiforme trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.